Literature DB >> 10084995

Lipoteichoic acid acts as an antagonist and an agonist of lipopolysaccharide on human gingival fibroblasts and monocytes in a CD14-dependent manner.

S Sugawara1, R Arakaki, H Rikiishi, H Takada.   

Abstract

CD14 has been implicated as a receptor of lipoteichoic acid (LTA) and other bacterial components as well as lipopolysaccharide (LPS). Since the structures of LTAs from various gram-positive bacteria are heterogeneous, we analyzed the effects of LTAs on the secretion of interleukin-8 (IL-8) by high- and low-CD14-expressing (CD14(high) and CD14(low)) human gingival fibroblasts (HGF). While Bacillus subtilis LTA had an IL-8-inducing effect on CD14(high) HGF which was considerably weaker than that of LPS, Streptococcus sanguis and Streptococcus mutans LTAs had practically no effect on the cells. B. subtilis LTA had only a weak effect on CD14(low) HGF, as did LPS. S. sanguis and S. mutans LTAs at a 1,000-fold excess each completely inhibited the IL-8-inducing activities of both LPS and a synthetic lipid A on CD14(high) HGF. The effect of LPS was also inhibited by the presence of an LPS antagonist, synthetic lipid A precursor IVA (LA-14-PP), with a 100-fold higher potency than S. sanguis and S. mutans LTAs and by anti-CD14 monoclonal antibody (MAb). S. sanguis and S. mutans LTAs, LA-14-PP, and anti-CD14 MAb had no significant effect on phorbol myristate acetate-stimulated IL-8 secretion by HGF. These LTAs also inhibited the IL-8-inducing activity of B. subtilis LTA on CD14(high) HGF, as did LA-14-PP and anti-CD14 MAb. The antagonistic and agonistic functions of LTAs were also observed with human monocytes. Binding of fluorolabeled LPS to human monocytes was inhibited by S. sanguis LTA, although the inhibition was 100 times weaker than that of LPS itself, and anti-CD14 MAb inhibited fluorolabeled LPS and S. sanguis LTA binding. Binding of LTAs to CD14 was also observed with nondenaturing polyacrylamide gel electrophoresis. These results indicate that LTAs act as antagonists or agonists via a CD14-dependent mechanism, probably due to the heterogeneous structure of LTAs, and that an antagonistic LTA might be a useful agent for suppressing the periodontal disease caused by gram-negative bacteria.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10084995      PMCID: PMC96505          DOI: 10.1128/IAI.67.4.1623-1632.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  A new chromogenic endotoxin-specific assay using recombined limulus coagulation enzymes and its clinical applications.

Authors:  T Obayashi; H Tamura; S Tanaka; M Ohki; S Takahashi; M Arai; M Masuda; T Kawai
Journal:  Clin Chim Acta       Date:  1985-06-30       Impact factor: 3.786

2.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein.

Authors:  S D Wright; R A Ramos; P S Tobias; R J Ulevitch; J C Mathison
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

3.  Induction of interleukin-1 and -6 in human gingival fibroblast cultures stimulated with Bacteroides lipopolysaccharides.

Authors:  H Takada; J Mihara; I Morisaki; S Hamada
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

Review 4.  Structural requirements of lipid A for endotoxicity and other biological activities.

Authors:  H Takada; S Kotani
Journal:  Crit Rev Microbiol       Date:  1989       Impact factor: 7.624

5.  Stimulation of monokine production by lipoteichoic acids.

Authors:  S Bhakdi; T Klonisch; P Nuber; W Fischer
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

6.  Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes.

Authors:  D T Golenbock; R Y Hampton; N Qureshi; K Takayama; C R Raetz
Journal:  J Biol Chem       Date:  1991-10-15       Impact factor: 5.157

7.  Lipoteichoic acid and interleukin 1 stimulate synergistically production of hepatocyte growth factor (scatter factor) in human gingival fibroblasts in culture.

Authors:  A Sugiyama; R Arakaki; T Ohnishi; N Arakaki; Y Daikuhara; H Takada
Journal:  Infect Immun       Date:  1996-04       Impact factor: 3.441

8.  IL-1 induction-capacity of defined lipopolysaccharide partial structures.

Authors:  H Loppnow; H Brade; I Dürrbaum; C A Dinarello; S Kusumoto; E T Rietschel; H D Flad
Journal:  J Immunol       Date:  1989-05-01       Impact factor: 5.422

9.  A nontoxic tumour necrosis factor induced by streptococcal lipoteichoic acids.

Authors:  H Usami; A Yamamoto; Y Sugawara; S Hamada; T Yamamoto; K Kato; S Kokeguchi; H Takada; S Kotani
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

10.  Antitumour effects of streptococcal lipoteichoic acids on Meth A fibrosarcoma.

Authors:  H Usami; A Yamamoto; W Yamashita; Y Sugawara; S Hamada; T Yamamoto; K Kato; S Kokeguchi; H Ohokuni; S Kotani
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

View more
  11 in total

1.  Subgingival Plaque in Periodontal Health Antagonizes at Toll-Like Receptor 4 and Inhibits E-Selectin Expression on Endothelial Cells.

Authors:  Thao T To; Pinar Gümüş; Nejat Nizam; Nurcan Buduneli; Richard P Darveau
Journal:  Infect Immun       Date:  2015-10-19       Impact factor: 3.441

2.  Structural decomposition and heterogeneity of commercial lipoteichoic Acid preparations.

Authors:  Siegfried Morath; Armin Geyer; Ingo Spreitzer; Corinna Hermann; Thomas Hartung
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

3.  Induction of keratinocyte growth factor 1 Expression by lipopolysaccharide is regulated by CD-14 and toll-like receptors 2 and 4.

Authors:  Edward E Putnins; Ali-Reza Sanaie; Qiang Wu; James D Firth
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

4.  Synergistic effect of muramyldipeptide with lipopolysaccharide or lipoteichoic acid to induce inflammatory cytokines in human monocytic cells in culture.

Authors:  S Yang; R Tamai; S Akashi; O Takeuchi; S Akira; S Sugawara; H Takada
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 5.  Modulation of release of proinflammatory bacterial compounds by antibacterials: potential impact on course of inflammation and outcome in sepsis and meningitis.

Authors:  Roland Nau; Helmut Eiffert
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

6.  Normal human fibroblasts express pattern recognition receptors for fungal (1-->3)-beta-D-glucans.

Authors:  P Kougias; D Wei; P J Rice; H E Ensley; J Kalbfleisch; D L Williams; I W Browder
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

7.  Transforming growth factor-beta inhibits lipopolysaccharide-stimulated expression of inflammatory cytokines in mouse macrophages through downregulation of activation protein 1 and CD14 receptor expression.

Authors:  K Imai; A Takeshita; S Hanazawa
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

8.  Lipoteichoic acids from Lactobacillus johnsonii strain La1 and Lactobacillus acidophilus strain La10 antagonize the responsiveness of human intestinal epithelial HT29 cells to lipopolysaccharide and gram-negative bacteria.

Authors:  Karine Vidal; Anne Donnet-Hughes; Dominique Granato
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

9.  Insertional inactivation of pac and rmlB genes reduces the release of tumor necrosis factor alpha, interleukin-6, and interleukin-8 induced by Streptococcus mutans in monocytic, dental pulp, and periodontal ligament cells.

Authors:  Marc Engels-Deutsch; Annelise Pini; Yoshihisa Yamashita; Yukie Shibata; Youssef Haikel; Marie Schöller-Guinard; Jean-Paul Klein
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Augmentation of Actinobacillus actinomycetemcomitans invasion of human oral epithelial cells and up-regulation of interleukin-8 production by saliva CD14.

Authors:  Atsuko Takayama; Aya Satoh; Tomoko Ngai; Takashi Nishimura; Keiji Ikawa; Takami Matsuyama; Hidetoshi Shimauchi; Haruhiko Takada; Shunji Sugawara
Journal:  Infect Immun       Date:  2003-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.